Combo Appears Effective After Anti-PD-1 Failure in Advanced Melanoma

Ipilimumab plus nivolumab demonstrated efficacy in a phase 2 trial of patients with advanced melanoma who failed prior anti-PD-1 therapy.

Related Keywords

Tennessee ,United States ,Germantown , ,National Cancer Institute ,Cancer Center ,Cancer Therapy Advisor ,West Cancer Center ,National Cancer ,